Invention Grant
- Patent Title: General amyloid interaction motif (GAIM)
-
Application No.: US17251351Application Date: 2019-06-14
-
Publication No.: US11692017B2Publication Date: 2023-07-04
- Inventor: Rajaraman Krishnan , Eva Asp , Ming Proschitsky , Richard Fisher
- Applicant: Amyl Therapeutics SRL
- Applicant Address: BE Seraing
- Assignee: Amyl Therapeutics SRL
- Current Assignee: Amyl Therapeutics SRL
- Current Assignee Address: BE Seraing
- Agency: Finnegan, Henderson, Farabow Garrett & Dunner, LLP
- International Application: PCT/US2019/037179 2019.06.14
- International Announcement: WO2019/241628A 2019.12.19
- Date entered country: 2020-12-11
- Main IPC: C07K14/47
- IPC: C07K14/47 ; A61K47/68 ; A61K38/00

Abstract:
The present invention relates to variants of the general amyloid interaction motif (GAIM) of bacteriophage gene 3 protein (g3p) and fusion proteins thereof. The GAIM variants and fusion proteins of the invention are partially or fully deimmunized and demonstrate superior binding and specificity to a diverse array of amyloid proteins, and exhibit enhanced amyloid remodeling and inhibition of amyloid aggregation. The present invention further relates to nucleic acids, vectors, host cells, and methods of making the GAIM variants and fusion proteins thereof. The present invention also relates to pharmaceutical compositions and methods of increasing bacteriophage infectivity, methods of detecting amyloid aggregates, and methods of diagnosing and/or treating a disease associated with misfolded and/or aggregated amyloid protein.
Public/Granted literature
- US20210246179A1 GENERAL AMYLOID INTERACTION MOTIF (GAIM) Public/Granted day:2021-08-12
Information query